Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy

Abstract

The Act of 12 May 2011 on the Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Uses and Medical Devices constitutes a major change of the reimbursement policy in Poland. The main aims of this Act were to rationalize the reimbursement policy and to reduce spending on reimbursed drugs. The Act seems to have met these goals: reimbursement policy (including pricing of reimbursed drugs) was overhauled and the expenditure of the National Health Fund on reimbursed drugs saw a significant decrease in the year following the Act's introduction. The annual savings achieved since then (mainly due to the introduction of risk sharing schemes), have made it possible to include new drugs into the reimbursement list and improve access to innovative drugs. However, at the same time, the decrease in prices of reimbursed drugs, that the Act brought about, led to an uncontrolled outflow of some of these drugs abroad and shortages in Poland. This paper analyses the main changes introduced by the Reimbursement Act and their implications. Since the Act came into force relatively recently, its full impact on the reimbursement policy is not yet possible to assess.

Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015

“…In their daily operations, health technology assessment (HTA) bodies make decisions or recommendations involving patients’ lives and large sums of public money. Given the many interests this inevitably attracts, and the global trends towards evidence-based policymaking and good governance, it is unsurprising that transparency has been a long established principle of good practice in HTA (Drummond et al ., 2008). Notably, it is part of the mission and value statement of the European Union network for Health Technology Assessment (2017), and has been put forward as a solution to the less-than-perfect utilisation of HTA by decision-makers (Sorenson et al ., 2008) or the low acceptance of its outputs by the public and stakeholders (Panteli et al ., 2015).…”

Path Analysis on Medical Expenditures of 855 Patients with Chronic Kidney Disease in a Hospital in Beijing

“…[ 17 ] Thus, it is suggested that medical management departments reconsider the necessity and accuracy for choosing the stage of disease and complications as the first and second subgroup factors in DRGs grouping of the area. [ 18 ]…”

Research of Medical Expenditure among Inpatients with Unstable Angina Pectoris in a Single Center

“…[20] While since the length of hospital stay is comparatively fluctuant, and that the control of hospitalization expenses is stricter that draws greater attention in China, we select inpatient medical expenditures as the statistical classification index to indicate the results of DRGs grouping in the study. [21] Nevertheless, the length of hospital stay is still one of the crucial factors affecting inpatient medical expenditures. Although setting the length of hospital stay as an independent variable will be helpful in explaining the linear equation toward hospitalization expenses, it is a form of medical output that can neither be adopted in the analysis of medical expenditure structure nor be used as the classification node.…”